Table 6

Antitumor activity of ZD1839, adriamycin, GEM, and EDX given alone or in combination against human lung tumors xenografted to nude mice

Two experiments of four mice/group.

TumorDrug compoundaAverage weight change (%)Average tumor diameterb,c (mm ± SE)Change in tumor volumeb,c (mm3)Tumor-free mice (no./total)
A549213.2 ± 2+11450 /8
ZD1839 (75)−210.1 ± 2+4850 /8
DOX (1)17.0 ± 1+1390 /8
ZD1839+ DOX−24.8 ± 1+120 /8
LX-1−314.3 ± 2+15750 /8
ZD1839 (75)−611.1 ± 2+6380 /8
EDX(45)−46.6 ± 1+910 /8
ZD1839+ EDX−72.6 ± 1−513 /8d
SK-LC-16111.1 ± 3+6520 /8
ZD1839 (50)−38.4 ± 2+3090 /8
ZD1839 (75)−48.0 ± 2+2290 /8
GEM (350)−24.8 ± 1+160 /8
EDX (45)−15.4 ± 1+390 /8
ZD1839(50)+ GEM−54.9 ± 1+180 /8
ZD1839(75)+ EDX−43.8 ± 2−231 /8d
  • a ZD1839 given (qd × 5) × 2 and cytotoxics given every 3–4 days × 4 at 3–4 day after implant.

  • b Initial tumor mass was 48–64 mg (4.7 ± 2 mm diameter).

  • c Measurements made 2–3 days after dose or at the nadir for a regressing tumor.

  • d Tumor regrowth in one of three (LX-1) and one of one (SK-LC-16) mice 21 days after treatment.